Home Administrative Billing & Reimbursement BlueCard® Health and Wellness Medical PEAR portal Pharmacy Products Quality Management

Prior authorization requirement for continuing low-dose opioid therapy now in effect

April 1, 2019

As of March 1, 2019, all Independence members, including those previously exempt, now require a prior authorization when continuing low-dose opioid therapy beyond five days, if they have not already received prior authorization approval from Independence. Providers received a letter with a list of their Independence patients who are affected by this change.  

As a reminder, as of July 1, 2017, Independence placed a five-day supply limit on all low-dose opioids. Members who, at that time, already had a prescription for greater than a five-day supply of low-dose opioids were temporarily exempted from this limit.

For more details regarding opioid and non-opioid therapy options, please refer to the CDC’s Checklist for prescribing opioids for chronic pain.

If you have any questions concerning the prior authorization process, please contact FutureScripts® at 1-888-678-7012.

FutureScripts is an independent company that provides pharmacy benefits management services.


This content was prepared for the Provider News Center and may not be reproduced in any way without the express written permission of Independence Blue Cross. Independence Blue Cross is an independent licensee of the Blue Cross and Blue Shield Association.
Connect with us     Facebook     Twitter     Flickr     YouTube     Walk the Talk    Independence Pinterest    Independence LinkedIn    Independence Instagram Site Map        Anti-Fraud        Privacy Policy        Legal        Disclaimer
© 2023 Independence Blue Cross.
Independence Blue Cross is an independent licensee of the Blue Cross and Blue Shield Association, serving the health insurance needs of Philadelphia and southeastern Pennsylvania.